SEC Filings
InflaRx Izicopan Study Reports No Serious Adverse Events Across 86 Healthy Participants
Previously announced results are now peer-reviewed, supporting the company's plans to develop the oral drug for inflammatory diseases.
InflaRx (IFRX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Previously announced results are now peer-reviewed, supporting the company's plans to develop the oral drug for inflammatory diseases.
SEC Filings
The company's own research puts peak sales potential at $1.5 - 2.0 billion, and it says €153.3 million in cash lasts through 2029.